Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
REGULATORY
Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
Japanese Prime Minister Shigeru Ishiba has pledged to take concrete measures from FY2026 to cut into the health coverage of OTC-like drugs, while freezing part of the government’s controversial plans to raise copay caps in the high-cost medical expense benefit…
To read the full story
Related Article
- MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
- Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
March 10, 2025
- Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
March 3, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
February 25, 2025
- CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
February 20, 2025
REGULATORY
- PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
- Drug Makers Can Refuse Diabetes Drug Supply over Improper Prescribing: JFTC
October 30, 2026
- Chuikyo Reps Back More Pharma Access to CEA Deliberations, Urge Neutrality
October 29, 2026
- FY2027 Revision: HCPs Press for Action on Drug Shortages, Negative Margins
October 29, 2026
- Zolgensma Cost-Effectiveness Analysis to Resume after Five-Year Halt
October 29, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…